Hikma Pharmaceuticals and Celltrion Inc. have signed exclusive licensing agreements to introduce six biosimilar treatments across the Middle East and North Africa (MENA), expanding access to affordable biologics in the region.
The deal strengthens a long-standing partnership between the multinational pharmaceutical company and the global biopharmaceutical leader. It marks a major step in improving availability of biosimilars for conditions in oncology, immune diseases, ophthalmology, allergic disorders and skeletal-related illnesses.
Under the agreement, Hikma will hold exclusive commercialisation rights in all MENA markets, while Celltrion will oversee development, manufacturing and supply. The companies aim to deliver high-quality, cost-effective alternatives to complex biologics, addressing barriers such as high costs and limited availability.
Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA, said: “We are proud to expand our partnership with Celltrion Inc., reinforcing our shared commitment to improving access to high quality, biosimilar treatments. These treatments have the potential to significantly improve quality of life for patients living with chronic, debilitating, or life-threatening conditions.”
The move also supports Hikma’s broader biotech strategy to enhance patient outcomes and reduce pressure on healthcare systems. Darwazah added: “The addition of these biosimilars enhances Hikma’s ability to serve hospital channels with a comprehensive portfolio of injectables and biologics, reinforcing its ambition to become the top hospital player in the region.”
With this expansion, Hikma continues to position itself as a leading provider of biosimilars in MENA, aiming to transform treatment standards and increase access to life-saving therapies.
